Ratings MDxHealth SA

Equities

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-20 pm EDT			5-day change	1st Jan Change
2.84 ^USD	-1.39%		-2.07%	-27.92%

May. 01	MDxHealth SA Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 01	Transcript : MDxHealth SA, Q1 2024 Earnings Call, May 01, 2024

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 61% by 2026.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The company's earnings releases usually do not meet expectations.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
MDXHEALTH SA	-27.92%	77.5M	-	-
MODERNA, INC.	+41.79%	54.04B		B-
IQVIA HOLDINGS INC.	-0.56%	41.92B		B
LONZA GROUP AG	+48.54%	41.96B		A
CELLTRION, INC.	-7.20%	28.35B		C
ICON PUBLIC LIMITED COMPANY	+12.59%	26.35B		B-
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	19B		B
BIO-TECHNE CORPORATION	+6.92%	13B		B+
UNITED THERAPEUTICS CORPORATION	+24.91%	12.19B		B+
MEDPACE HOLDINGS, INC.	+29.60%	12.28B		C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality